Active Ingredient History
Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia in people who have not been helped by other types of chemotherapy or whose condition has improved but then worsened following treatment with other types of chemotherapy. Arsenic trioxide acts through activation of Jun N-terminal kinase (JNK), activator protein-1, and inhibition of dual-specificity phosphatases. Although the exact mechanisms under which ATO exerts its therapeutic effect in acute promyelocytic leukemia cancer cells are not well elucidated. It was shown that apoptotic mechanisms involved the induction of phosphatidylserine externalization, caspase-3 activation, and nucleosomal DNA fragmentation. Adverse reactions described are leukocytosis, nausea, vomiting, diarrhea, and abdominal pain, fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Promyelocytic, Acute (approved 2000)
Arsenic Trioxide (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2/Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Small Cell (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
GATA2 Deficiency (Phase 1)
Glioblastoma (Phase 1)
Gliosarcoma (Phase 1)
Graft vs Host Disease (Phase 2)
Hematologic Diseases (Phase 1)
HIV Infections (Phase 1)
Immune System Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 4)
Li-Fraumeni Syndrome (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacological and Toxicological Phenomena (Phase 1/Phase 2)
Polycythemia Vera (Phase 1)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Retinoblastoma (Phase 2)
Sarcoma (Phase 2)
Stem Cell Transplantation (Phase 1/Phase 2)
Testicular Neoplasms (Phase 2)
Thrombocythemia, Essential (Phase 1)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
